Belarusian medications are entering new markets. They will be marketed in the US.
Antibiotics are being prepared for certification. The audit should be completed by the end of the year. This certificate opens the way not only to the United States, but also to the other foreign markets. As for the European Union, one Belarusian plant has already received permission.
Last year, foreign companies bought Belarusian medicines worth $140 million. Geography – 30 countries. At the same time, foreign partners are interested not only in direct supplies, but also in the creation of joint ventures. Direct proof of this is a new project with Uzbekistan. In collaboration on the territory of the Asian country the partners will produce devices for blood transfusion, probes and drainages. Under a similar scheme, Belarusian pharmaceutical plants intend to work with Georgia and Tajikistan.